GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Avanir Pharmaceuticals (AVNR) [hlAlert]

Rating:
Overweight
AVNR
up 472.97 %

Avanir Pharmaceuticals (AVNR) rated Overweight by Piper Jaffray

Posted on: Friday,  Jan 4, 2013  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Avanir Pharmaceuticals (NASDAQ: AVNR) on 01/04/2013, when the stock price was $2.96. Since
then, Avanir Pharmaceuticals has gained 472.97% as of 01/12/2015's recent price of $16.96.
If you would have followed this Piper Jaffray's recommendation on AVNR, you would have gained 472.97% of your investment in 738 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2013 8:25 AM Buy
None
2.96
as of 12/13/2013
1 Week down  -34.56 %
1 Month down  -36.32 %
3 Months down  -30.39 %
1 YTD down  -4.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy